Clinical Trial Update: Study Evaluating the Efficacy and Safety of the Addition of Ivosidenib to Oral Azacitidine (Onureg®) in Patients Over 55 With Acute Myeloid Leukemia (AML) and IDH1 Mutation, in Complete Remission After Intensive Chemotherapy. [Phase 2]

View source ↗

Summary

A Phase 2 trial is evaluating whether adding ivosidenib to oral azacitidine (Onureg) improves outcomes in patients over 55 with IDH1-mutated acute myeloid leuke…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Ivosidenib (ivosidenib)
• Onureg (azacitidine)

Snippet

Sponsor: French Innovative Leukemia Organisation | Conditions: Acute Myeloid Leukemia | Phase 2 | Status: NOT_YET_RECRUITING